Cargando…
Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?
Seventy percent of breast tumors are estrogen receptor (ER) positive. Although endocrine therapy is successful for the majority of patients with ER-positive tumors, approximately 30% show de novo or acquired resistance and the underlying molecular mechanisms and biomarkers that predict such resistan...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096967/ https://www.ncbi.nlm.nih.gov/pubmed/21062517 http://dx.doi.org/10.1186/bcr2718 |